Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	36.57	65.81	14.31	46.33	71.14	250.73
Short-Term Investments	14.24	28.3	130.98	206.67	330.17	160.91
Cash & Short-Term Investments	50.8	94.11	145.29	253	401.31	411.64
Cash Growth	-40.09%	-35.23%	-42.57%	-36.96%	-2.51%	359.76%
Receivables	0.98	1.2	2.41	11.74	8.03	19.06
Prepaid Expenses	3.4	2.52	5.41	20.51	39.1	4.8
Other Current Assets	-	-	-	30	-	35.66
Total Current Assets	55.18	97.83	153.11	315.24	448.44	471.17
Property, Plant & Equipment	9.7	11.77	14.45	17.96	29.02	24.09
Long-Term Investments	2.5	1.61	2.78	2.01	3.91	4.89
Goodwill	-	-	-	10.51	10.51	10.51
Other Intangible Assets	-	-	-	2.13	2.63	3.15
Other Long-Term Assets	2.01	1.98	0.61	0.68	1.43	25.96
Total Assets	69.39	113.2	170.95	348.53	495.94	539.77
Accounts Payable	5.9	6.44	4.65	21.08	27.97	1.47
Accrued Expenses	10.76	13.13	18.64	26.42	30.55	30.08
Current Portion of Long-Term Debt	-	-	16.77	-	-	-
Current Portion of Leases	2.74	2.5	2.41	2.8	2.6	2.33
Current Unearned Revenue	0.04	-	0.11	2.56	4.62	7.58
Other Current Liabilities	50.38	13.26	-	44	-	0.25
Total Current Liabilities	69.82	35.33	42.57	96.87	65.74	41.71
Long-Term Debt	-	-	-	16.61	14.96	18.66
Long-Term Leases	7.28	9.37	11.03	12.66	15.46	18.06
Long-Term Unearned Revenue	-	-	-	-	0.06	0.12
Long-Term Deferred Tax Liabilities	-	-	-	0.03	0.03	0.03
Other Long-Term Liabilities	-	-	-	-	0.01	0.06
Total Liabilities	77.11	44.69	53.6	126.17	96.27	78.63
Common Stock	0.05	0.04	0.02	0.02	0.22	0.19
Additional Paid-In Capital	1,812	1,799	1,741	1,711	1,610	1,367
Retained Earnings	-1,819	-1,730	-1,623	-1,488	-1,210	-906.2
Comprehensive Income & Other	-0.65	-0.68	-0.66	-0.7	-0.28	-0.26
Total Common Equity	-7.72	68.5	117.35	222.36	399.67	461.14
Shareholders' Equity	-7.72	68.5	117.35	222.36	399.67	461.14
Total Liabilities & Equity	69.39	113.2	170.95	348.53	495.94	539.77
Total Debt	10.02	11.87	30.21	32.07	33.02	39.05
Net Cash (Debt)	40.78	82.25	115.08	220.92	368.29	372.59
Net Cash Growth	-43.64%	-28.53%	-47.91%	-40.01%	-1.16%	-
Net Cash Per Share	1.05	3.03	5.19	11.11	21.16	28.82
Filing Date Shares Outstanding	53.57	36.67	23.37	21.68	18.12	17.3
Total Common Shares Outstanding	53.57	36.1	22.79	21.09	18.12	15.57
Working Capital	-14.64	62.5	110.54	218.37	382.7	429.46
Book Value Per Share	-0.14	1.90	5.15	10.54	22.06	29.62
Tangible Book Value	-7.72	68.5	117.35	209.72	386.53	447.48
Tangible Book Value Per Share	-0.14	1.90	5.15	9.94	21.34	28.74
Machinery	-	8.36	9.9	13.49	20.59	12.16
Leasehold Improvements	-	11.76	15.92	15.8	15.8	15.18

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q